Public Citizen's Health Research Group files a citizen petition June 3 requesting that FDA withdraw trovafloxacin from the market in response to 140 post-marketing reports of liver toxicity ("The Pink Sheet" May 31, p. 6). The HRG petition maintains that "the removal of Trovan from the market will not deprive doctors or patients," given that there are seven other fluoroquinolone antibiotic products available in the U.S. HRG asserts that there was evidence of liver damage caused by Trovan prior to FDA approval based on three preclinical studies. The group asserted that "this is yet another instance of a lower standard for approving drugs in recent years"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth